{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:15:34Z","timestamp":1784744134760,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T00:00:00Z","timestamp":1492992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.eplepsyres.2017.04.018","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T00:17:30Z","timestamp":1493165850000},"page":"41-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters"],"prefix":"10.1016","volume":"134","author":[{"given":"Barry E.","family":"Gidal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama","family":"Maganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Laurenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Verbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Schuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0005","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2133\/dmpk.DMPK-12-RG-134","article-title":"Mechanism-based inhibition profiles of erythromycin and clarithromycin with cytochrome P450 3A4 genetic variants","volume":"28","author":"Akiyoshi","year":"2013","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0010","first-page":"47","article-title":"Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general","volume":"2","author":"Boxenbaum","year":"1999","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2012.12.006","article-title":"Novel treatment options for epilepsy: focus on perampanel","volume":"70","author":"Franco","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0020","series-title":"FYCOMPA, (perampanel) US Prescribing Information","year":"2016"},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0025","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/epi.12240","article-title":"Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures","volume":"54","author":"Gidal","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0030","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1212\/WNL.0000000000001558","article-title":"Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy","volume":"84","author":"Gidal","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0035","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.2042-7158.2010.01202.x","article-title":"Mechanism of cytochrome P450-3A inhibition by ketoconazole","volume":"63","author":"Greenblatt","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0040","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/dmd.110.036103","article-title":"Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions","volume":"39","author":"Guest","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0045","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1124\/dmd.112.050732","article-title":"Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole","volume":"41","author":"Han","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0050","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2133\/dmpk.24.53","volume":"24","author":"Jamei","year":"2009","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0055","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.ddtec.2012.09.011","article-title":"Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI)","volume":"10","author":"Kamel","year":"2013","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0060","series-title":"NIZORAL, (ketoconazole) Prescribing Information","year":"2011"},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist","volume":"56","author":"Patsalos","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-0404.2008.01004.x","article-title":"Benzodiazepines in epilepsy: pharmacology and pharmacokinetics","volume":"118","author":"Riss","year":"2008","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0075","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ane.12100","article-title":"Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist","volume":"127","author":"Rogawski","year":"2013","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0080","series-title":"SPORANOX, (itraconazole) 100 mg capsule Data Sheet","year":"2013"},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0085","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0091270008331133","article-title":"Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm","volume":"49","author":"Stoch","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0090","series-title":"Drug Interaction Studies \u2013 Study Design, Data Analysis, and Implications for Dosing and Labeling. Draft Guidance","author":"U.S. Department of Health and Human Services","year":"2012"},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0095","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/j.1875-9114.2012.01028.x","article-title":"Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes","volume":"32","author":"Walzer","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0100","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2125.2010.03656.x","article-title":"Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles","volume":"69","author":"Yamazaki","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0105","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1684\/epd.2014.0714","article-title":"Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs","volume":"16","author":"Zaccara","year":"2014","journal-title":"Epileptic. Disord."},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0110","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/0091270008331196","article-title":"Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study","volume":"49","author":"Zhao","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0115","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/clpt.2010.298","article-title":"Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review","volume":"89","author":"Zhao","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.eplepsyres.2017.04.018_bib0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/clpt.2012.68","article-title":"Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions","volume":"92","author":"Zhao","year":"2012","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121117302565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121117302565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:36:25Z","timestamp":1760276185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121117302565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":24,"alternative-id":["S0920121117302565"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2017.04.018","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2017.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}